The investigation of guillain-barre syndrome and prognosis

Aim: Guillain-Barre Syndrome (GBS) is an immune-mediated disease of peripheral nervous system. It is important to estimate the prognosis because of disability burden and morbidity. In addition to clinical features and disease severity scales, serum biomarkers were used to estimate prognosis. We aimed to determine the subtypes, demographic and clinical characteristics of GBS patients, and the factors affecting the short-term prognosis.Material and Methods: The medical files of 94 patients who were followed up with diagnosis of GBS between January 2011 and January 2018 were retrospectively reviewed. Demographic and clinical features, disease severity scores, and neutrophil/lymphocyte (N/L) ratios were determined, and the effects of these parameters on short-term prognosis were investigated.Results: Most of the patients (60.6%) had acute inflammatory demyelinating polyneuropathy (AIDP) subtype. A majority of the cases were men and were in 5 to 7th decades of age. There was no seasonal relevance with the disease. 77% of the cases had albuminocytologic dissociation. The short-term prognosis was associated with age, respiratory failure, cranial nerve involvement and N/L ratio.Conclusion: It is important to estimate the prognosis in GBS. In our study, age, respiratory failure, cranial nerve involvement and N/L ratio were found as related factors with short-term prognosis.

PDF

___

1. Van den Berg B, Walgaard C, Drenthen J, et al. Guillain - Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neuro 2014;10:469-82.
2. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-50.
3. Nachamkin I, Arzarte Barbosa P, Ung H, et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology 2007;69:1665-71.
4. McGrogan A, Madle GC, Seaman HE, et al. The epidemiology of Guillain-Barré syndrome worldwide. Neuroepidemiology 2009;32:150-63.
5. Cheng Q, Jiang GX, Press R, et al. Clinical epidemiology of guillain–barré syndrome in adults in sweden 1996–97: a prospective study. Eur J Neurol 2000;7:685-92.
6. Fokkink W-JR, Walgaard C, Kuitwaard K, et al. Association of albumin levels with outcome in intravenous immunoglobulin–treated guillain-barré syndrome. JAMA Neurol 2017;74:189-96.
7. Strauss J, Aboab J, Rottmann M, et al. Plasma cortisol levels in guillain-barré syndrome. Crit Care Med 2009;37:2436-40.
8. Huang Y, Ying Z, Quan W, et al. The clinical significance of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in Guillain–Barré syndrome. Int J Neurosci 2018;128:729-35.
9. Wang Y, Li G, Yang S, et al. Fasting glucose levels correlate with disease severity of Guillain-Barre syndrome. PloS one 2015;10:e014575.
10. Sipilä JO, Kauko T, Soilu-Hänninen M. Admission sodium level and prognosis in adult Guillain–Barré syndrome. Int J Neurosci 2017;127:344-9.
11. Sahin S, Cinar N, Karsidag S. Are cerebrospinal fluid protein levels and plasma neutrophil/lymphocyte ratio associated with prognosis of Guillain Barré syndrome? Neurol Int 2017;9:7032.
12. Hughes R, Newsom-Davis J, Perkin G, et al. Controlled trial of prednisolone in acute polyneuropathy. Lancet Neurol 1978;312:750-3.
13. Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001;58:893-8.
14. Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty’s Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O’Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp.[8] 64 and 94 Figures. Brain 2010;133:2838-44.
15. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: an update. J Clin Neurosci 2009;16:733-41.
16. Cea G, Jara P, Quevedo F. Clinical features of Guillain-Barré syndrome in 41 patients admitted to a public hospital. Rev Med Chil 2015;143:183-9.
17. Lyu RK, Tang LM, Cheng SY, et al. Guillain-barré syndrome in taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997;63:494-500.
18. Sedano M, Calleja J, Canga E, et al. Guillain-barré syndrome in cantabria, spain. an epidemiological and clinical study. Acta Neurol Scand 1994;89:287-92.
19. Gazioğlu S, Tomak T, Boz C. Guillain Barre Sendromunda Klinik Özellikler ve Prognoz. J Neurol Sci [Turk]. 2013;34:124-34.
20. Akil E, Varol S, Taskin A, ve ark. Guillain-Barre sendromunda klinik ve demografik özellikler/Clinical and demographic characteristics of Guillain-Barre syndrome. Dicle Tip Dergisi 2014;41:707.
21. Terzi M, Türker H, Musa O. Guillain Barre Sendromunda klinik ve demografik özellikler. Fırat Tıp Dergisi. 2007;12:112-4.
22. Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol 2001;14:605-13.
23. Koga M, Yuki N, Hirata K. Antecedent symptoms in Guillain–Barré syndrome: an important indicator for clinical and serological subgroups. Acta Neurol Scand 2001;103:278-87.
24. Ropper AH. Guillain-Barré syndrome. Contemporary neurology series 1991;34:161-9.
25. Hankey G. Guillain-Barre syndrome in Western Australia, 1980-1985. Med J Aust 1987;146:130-3.
26. Larsen JP, Kvale G, Nyland H. Epidemiology of the Guillain-Barré syndrome in the county of Hordaland, Western Norway Acta Neurol Scand 1985;71:43-7.
27. Boucquey D, Sindic CJ, Lamy M, et al. Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome. J Neurol Sci 1991;104:56-63.
28. Winner SJ, Evans JG. Age-specific incidence of Guillain-Barré syndrome in Oxfordshire. Q J Med 1990;77:1297-304.
29. Färkkilä M, Kinnunen E, Weckström P. Survey of Guillain-Barré syndrome in southern Finland. Neuroepidemiology 1991;10:236-41.
30. Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2013;137:33-43.
31. Löffel NB, Rossi LN, Mumenthaler M, et al. The Landry-Guillain-Barré syndrome: Complications, prognosis and natural history in 123 cases. J Neurol Sci 1977;33:71-9.
32. Dhadke SV, Dhadke VN, Bangar SS, et al. Clinical profile of Guillain Barre syndrome. J Assoc Physicians India 2013;61:168-72.
33. Bhargava A, Banakar BF, Pujar GS, et al. A study of Guillain–Barré syndrome with reference to cranial neuropathy and its prognostic implication. J Neurosci Rural Pract 2014;5:S43.
34. Hahn AF. Guillain-barré syndrome. Lancet Neurol 1998;352:635-41.
35. Hughes RA, Wijdicks EF, Barohn R, et al. Quality standards subcommittee of the American academy of neurology. practice parameter: immunotherapy for guillain-barré syndrome: report of the quality standards subcommittee of the American academy of neurology. Neurology 2003;61:736-40.
36. Van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007;6:589-94.
37. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23:347-53.
38. Ozdemir HH. Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in Guillain-Barré syndrome. Arq Neuropsiquiatr 2016;74:718-22.
39. Tokgoz S, Keskin S, Kayrak M, et al. Is neutrophil/lymphocyte ratio predict to short-term mortality in acute cerebral infarct independently from infarct volume? J Stroke Cerebrovasc Dis 2014;23:2163-8.
40. Kuyumcu ME, Yesil Y, Oztürk ZA, et al. The evaluation of neutrophil-lymphocyte ratio in Alzheimer’s disease. Dement Geriatr Cogn Disord 2012;34:69-74.